Safety and feasibility of targeted agent combinations in solid tumours
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and feasibility of targeted agent combinations in solid tumours
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 10, Issue 3, Pages 154-168
Publisher
Springer Nature
Online
2013-01-29
DOI
10.1038/nrclinonc.2012.245
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results
- (2017) V. Papadimitrakopoulou et al. JOURNAL OF CLINICAL ONCOLOGY
- DUX study: A phase II study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer.
- (2017) A. J. Weickhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial.
- (2017) B. J. Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC).
- (2017) C. W. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC).
- (2017) N. B. Leighl et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC).
- (2017) B. Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab (B) in combination with sorafenib (S) in patients (pts) with advanced malignant melanoma.
- (2017) D. Mahalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
- (2017) R. S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship of incomplete inhibition of PI3K pathway signaling and efficacy of cetuximab in KRAS wild-type colorectal cancers.
- (2017) Ryan Bruce Corcoran et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumor Heterogeneity: Evolution through Space and Time
- (2012) C. Swanton CANCER RESEARCH
- Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)
- (2012) K. A. Margolin et al. CLINICAL CANCER RESEARCH
- Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma
- (2012) M. A. Davies et al. CLINICAL CANCER RESEARCH
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy
- (2012) J. S. Logue et al. GENES & DEVELOPMENT
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
- (2012) J. G. Greger et al. MOLECULAR CANCER THERAPEUTICS
- Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers
- (2011) Kristoffer S. Rohrberg et al. ACTA ONCOLOGICA
- Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study
- (2011) C. Gridelli et al. ANNALS OF ONCOLOGY
- A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
- (2011) G. Grignani et al. ANNALS OF ONCOLOGY
- Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
- (2011) G Procopio et al. BRITISH JOURNAL OF CANCER
- Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer
- (2011) Philip A. Philip et al. CANCER
- A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma
- (2011) Andrea L. Harzstark et al. CANCER
- Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma
- (2011) Carlos H. Barrios et al. CANCER
- Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes
- (2011) Katherine Ververis et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib
- (2011) Y. Y. Janjigian et al. CLINICAL CANCER RESEARCH
- Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial
- (2011) D. M. Davies et al. CLINICAL CANCER RESEARCH
- Phase I Trial of Everolimus Plus Sorafenib for Patients with Advanced Renal Cell Cancer
- (2011) Robert J. Amato et al. Clinical Genitourinary Cancer
- A phase I study of sirolimus and bevacizumab in patients with advanced malignancies
- (2011) E.E.W. Cohen et al. EUROPEAN JOURNAL OF CANCER
- Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2011) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?
- (2011) Sophie Postel-Vinay et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2011) Ronald B. Natale et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer
- (2011) R. W. Humphrey et al. JNCI-Journal of the National Cancer Institute
- Phase I Study of Sunitinib and Erlotinib in Advanced Nonsquamous Non-small Cell Lung Cancer
- (2011) Shannon E. O'Mahar et al. Journal of Thoracic Oncology
- Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
- (2011) Roy S Herbst et al. LANCET
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
- (2011) Sylvie Négrier et al. LANCET ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Imaging the coordination of multiple signalling activities in living cells
- (2011) Christopher M. Welch et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase II Trial of Bevacizumab plus Everolimus for Patients with Refractory Metastatic Colorectal Cancer
- (2011) I. Altomare et al. ONCOLOGIST
- Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma
- (2010) Robert J. Motzer et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging
- (2010) A.-M. C. Dingemans et al. ANNALS OF ONCOLOGY
- Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
- (2010) Carlos H. Barrios et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer
- (2010) I M E Desar et al. BRITISH JOURNAL OF CANCER
- Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib
- (2010) T W Flaig et al. BRITISH JOURNAL OF CANCER
- Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
- (2010) J-M Lee et al. BRITISH JOURNAL OF CANCER
- Bevacizumab and everolimus in the treatment of patients with metastatic melanoma
- (2010) John D. Hainsworth et al. CANCER
- A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
- (2010) Andrew H. Ko et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer
- (2010) J. S. W. Lind et al. CLINICAL CANCER RESEARCH
- Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma
- (2010) S. Tariq Mahmood et al. INTERNATIONAL JOURNAL OF CANCER
- Toxicity of Sunitinib Plus Bevacizumab in Renal Cell Carcinoma
- (2010) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
- (2010) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzastaurin in the Treatment of Recurrent Glioblastoma: A Promise That Did Not Materialize
- (2010) Evanthia Galanis et al. JOURNAL OF CLINICAL ONCOLOGY
- Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study
- (2010) Sam J. Lubner et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma
- (2010) John D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- (2010) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
- (2010) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer
- (2010) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
- (2010) Katharine A. Price et al. Journal of Thoracic Oncology
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
- (2010) Federico Cappuzzo et al. LANCET ONCOLOGY
- Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort
- (2010) M. Quintela-Fandino et al. MOLECULAR CANCER THERAPEUTICS
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Preclinical development of molecular-targeted agents for cancer
- (2010) Alberto Ocana et al. Nature Reviews Clinical Oncology
- Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements
- (2010) Shivanni Kummar et al. NATURE REVIEWS DRUG DISCOVERY
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- A Phase I/II Trial of Trastuzumab plus Erlotinib in Metastatic HER2-Positive Breast Cancer: A Dual ErbB Targeted Approach
- (2009) Carolyn D. Britten et al. Clinical Breast Cancer
- A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors
- (2009) B. I. Rini et al. CLINICAL CANCER RESEARCH
- Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma
- (2009) Premal H. Patel et al. Clinical Genitourinary Cancer
- Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck
- (2009) J. Simon W. Stewart et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
- (2009) Melanie B. Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
- (2009) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
- (2009) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
- (2009) Ezra EW Cohen et al. LANCET ONCOLOGY
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer
- (2008) A. Santoro et al. ANNALS OF ONCOLOGY
- Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
- (2008) J. Bellmunt et al. ANNALS OF ONCOLOGY
- Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
- (2008) David M. Jackman et al. CANCER
- A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
- (2008) C. L. Arteaga et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
- (2008) M. N. Dickler et al. CLINICAL CANCER RESEARCH
- Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
- (2008) C. C. Portera et al. CLINICAL CANCER RESEARCH
- Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer
- (2008) Magnus Rizell et al. International Journal of Clinical Oncology
- Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer
- (2008) Anna Maria Storniolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Recurrent Priapism Related to Oxaliplatin Infusion
- (2008) Antoine Adenis et al. JOURNAL OF CLINICAL ONCOLOGY
- Anthracyclines: The First Generation of Cytotoxic Targeted Agents? A Possible Dream
- (2008) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study
- (2008) Lucio Crinò et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
- (2008) Nilofer S. Azad et al. JOURNAL OF CLINICAL ONCOLOGY
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
- (2008) Alberto F. Sobrero et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
- (2008) Matthew H. Kulke et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
- (2008) Michael D. Prados et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
- (2008) Teri N. Kreisl et al. JOURNAL OF NEURO-ONCOLOGY
- Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients with Refractory Non-small Cell Lung Cancer (NSCLC): A Phase I Study
- (2008) Suresh Ramalingam et al. Journal of Thoracic Oncology
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
- (2008) John J. Bissler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
- (2008) M Scaltriti et al. ONCOGENE
- Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor
- (2008) Alan P. Brown et al. TOXICOLOGIC PATHOLOGY
- Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications
- (2008) Giampaolo Tortora et al. Nature clinical practice. Oncology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started